New drug targets inflammation in Hard-to-Treat Behçet's disease
NCT ID NCT07634848
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This trial tests a drug called ivarmacitinib in people with Behçet's disease who have not improved with standard treatments. Ivarmacitinib blocks a key inflammation pathway (JAK-STAT) to reduce symptoms. Participants take the drug daily for 24 weeks, and researchers monitor their response and safety.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Ivarmacitinib
- What this could lead to
- If successful, this could offer a new treatment option for people with Behçet's disease who do not respond to current therapies.
- What could go wrong
- This is a small, early-phase trial with only 30 participants and no comparison group. Results may not apply to all patients, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ① Meets the 1990 ISG diagnostic criteria for Behçet's syndrome \[9\]; * Aged 18-70 years; ③ Has shown an inadequate response to treatment after at least 6 months of therapy with glucocorticoids, at least two immunosuppressants, and/or biologics (including TNF-α inhibitors and IL-6 inhibitors); * Agrees to receive treatment with a new targeted therapy Exclusion Criteria: * ① Patients with one or more other autoimmune diseases; * Patients who have undergone major surgery within 4 weeks prior to enrollment, or who are scheduled to undergo elective surgery during the study; ③ Patients with a confirmed acute or chronic active infection (e.g., bacterial, viral \[such as EBV, CMV, HIV, or active hepatitis virus\]) within 4 weeks prior to enrollment; ④ Patients with a current or past history of any malignancy; * Female patients who are pregnant or within 6 months postpartum; * Patients with severe liver failure (Child-Pugh Class C) or end-stage renal disease (dialysis-dependent).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Behcet's syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Rheumatology and Immunology, Peking University People's Hospital
Beijing, Beijing Municipality, China